Kraig Biocraft Laboratories, Inc. (KBLB)
OTCMKTS · Delayed Price · Currency is USD
0.14054
+0.01154 (8.95%)
At close: Apr 15, 2026

KBLB Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
3.212.912.381.942.56
Research & Development
0.170.160.240.180.2
Operating Expenses
3.373.072.612.122.76
Operating Income
-3.37-3.07-2.61-2.12-2.76
Interest Expense
-0.57-0.53-0.48-1.72-5.36
Interest & Investment Income
0.010.070.11--
EBT Excluding Unusual Items
-3.93-3.53-2.99-3.84-8.12
Gain (Loss) on Sale of Investments
0.310.130.060-0.01
Asset Writedown
---0.1--
Other Unusual Items
----0.09
Pretax Income
-3.62-3.4-3.03-3.84-8.05
Net Income
-3.62-3.4-3.03-3.84-8.05
Net Income to Common
-3.62-3.4-3.03-3.84-8.05
Shares Outstanding (Basic)
1,0591,0381,033974878
Shares Outstanding (Diluted)
1,0591,0381,033974878
Shares Change (YoY)
2.03%0.51%6.04%11.02%3.41%
EPS (Basic)
-0.00-0.00-0.00-0.00-0.01
EPS (Diluted)
-0.00-0.00-0.00-0.00-0.01
Free Cash Flow
-1.79-1.84-1.25-1.89-1.9
Free Cash Flow Per Share
-0.00-0.00-0.00-0.00-0.00
EBITDA
-3.35-3.05-2.59-2.09-2.73
D&A For EBITDA
0.030.030.030.030.03
EBIT
-3.37-3.07-2.61-2.12-2.76
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.